Zydus Cadila (symbolic photo)
Even after getting the approval of the three-dose vaccine, its use has not yet started in the country. A few days ago, the government said preparations were underway to make Zydus Cadila’s COVID-19 vaccine available to the public, although price was an “obvious issue”.
The Drugs Controller General of India (DCGI) has approved the Phase-3 clinical trial of indigenous pharma company Zydus Cadila for its two-dose COVID-19 vaccine ZyCoV-D (ZyCoV-D). The company said in a statement, ‘The Phase III trial of the two-dose COVID vaccine has been approved.’ ZyCoV-D is the world’s first DNA vaccine against COVID-19.
Jaykov-D is also the first indigenous vaccine, which was also tested on children. Its three-dose vaccine was approved for emergency use in August. In the interim clinical trial data, the effective efficacy of the vaccine against COVID-19 was reported to be 66 percent. However, the company has not yet shared the detailed information of its study or sent it for peer review.
After the approval of the three-dose vaccine by the Ministry of Science and Technology, Government of India, it was said that the third phase clinical trial of this vaccine was done on more than 28,000 people. It showed 66.6% efficacy in symptomatic RT-PCR positive cases. This is the largest vaccine trial for COVID-19 in India so far. This vaccine was also seen to be very effective in the first and second phase clinical trials.
Prime Minister Narendra Modi, while addressing the 76th session of the United Nations General Assembly on September 25, said that India has developed the world’s first DNA vaccine against COVID-19, which can be administered to all people above the age of 12 years. .
Negotiations are on to reduce the price
Even after getting the approval of the three-dose vaccine, its use has not yet started in the country. A few days ago, the government said that preparations were underway to make Zydus Cadila’s COVID-19 vaccine available to the public, although the price was an “obvious issue”. The company has fixed a price of Rs 1,900 for three doses of the vaccine, but the government is in talks to reduce the price. NITI Aayog member (health) Dr. VK Paul had said, “Talks are on and a decision will be taken soon. With full preparation, it will become a part of the country’s national immunization programme.”
According to the company, Jaykov-D is a plasmid DNA vaccine. Plasmids are a small part of the DNA found in humans. This vaccine prepares the ‘spike protein’ of the corona virus with the help of cells in the human body, which helps the body to identify the important part of the corona virus. In this way the immune system of this virus is prepared in the body.
Also read- Plea seeking probe into oxygen shortage during second wave dismissed, Supreme Court said – easy to criticize the government
Also read- Hanging bridge broken in Karimganj, Assam, 30 children on the bridge fell into the river, it was ready three years ago